key: cord-0761062-quomylrq authors: Power, Monique; Azad, Taha; Bell, John C.; MacLean, Allyson M title: Plant-based expression of SARS-CoV-2 antigen for use in an oral vaccine date: 2021-12-09 journal: bioRxiv DOI: 10.1101/2021.12.07.471131 sha: d184093ce3226f47b9a20a177e36cbafc2b118cb doc_id: 761062 cord_uid: quomylrq Oral and intra-nasal vaccines represent a key means of inducing mucosal-based immunity against infection with SARS-CoV-2, yet such vaccines represent only a minority of candidates currently in development. In this brief communication, we assessed the expression of the SARS-CoV-2 Receptor Binding Domain (RBD) subunit of the surface-exposed Spike glycoprotein in the leaves of nine edible plant species (lettuce, spinach, collard greens, tomato, cucumber, radish, arugula, pepper, and Coho greens), with a goal of identifying a suitable candidate for the development of an oral vaccine against COVID-19. We report lettuce (Lactuca sativa L. cv. Hilde II Improved) to be a preferred host to support in planta expression of SARS-CoV-2 RBD, representing an important first step towards development of a plant-based oral vaccine. protective against disease 1 . A wide variety of plants and the model green alga Chlamydomonas reinhardtii have been explored for their potential to act as oral vaccines against an equally wide range of diseases. Examples involving human viruses include (and are not limited to) Hepatitis B in potato, tomato, lettuce, maize and C. reinhardtii [3] [4] [5] [6] [7] , HIV in tobacco, lettuce, carrot and C. reinhardtii 6, [8] [9] [10] , HPV in tobacco, tomato and C. reinhardtii [11] [12] [13] , rabies virus in maize 14 , and influenza virus in maize 15 . Plant-based oral vaccines against bacterial and protozoal human pathogens have also been successfully created against, for example Enterotoxigenic Escherichia coli in rice 16 ; Mycobacterium tuberculosis in carrot 17 ; Vibrio cholerae in rice 18 , maize 19 and potato 20 ; Plasmodium in tobacco, lettuce 21 , rapeseed 22 and C. reinhardtii 23 ; and Toxoplasma gondii in tobacco 24 . In an example that is highly relevant to our research, a subunit of the Spike protein of SARS-CoV (S1) was shown to induce SARS-CoV-specific IgA in mice after oral ingestion of transgenic tomato 25 . The mechanisms by which plant-based oral vaccines elicit an immune response have been studied and reviewed in detail 1 . Ingested foods do not typically elicit an immune response, thus, to ensure efficient uptake by microfold cells within gut-associated lymphoid tissue, antigens may be fused to mucosal carrier proteins (e.g., B subunit of cholera toxin; CTxB). Plant-based oral vaccines have been shown to induce both cellular and humoral immunity within the mucosal and systemic immune systems 1, 26 . Because the initial site of SARS-CoV-2 infection is within the respiratory mucosa, efforts to develop mucosal vaccines (oral or intra-nasal) are an important complement to conventional vaccines 2 . This study aimed to optimize methods for the in planta expression of recombinant protein corresponding to the Receptor Binding Domain (RBD) subunit of the surface-exposed Spike glycoprotein of SARS-CoV-2. The RBD is a primary target of vaccine strategies against COVID-19, and most neutralizing antibodies against SARS-CoV-2 correspond to RBD 27, 28 . We (Fig.1a) . Amongst the edible plants, the highest and most consistent expression of RBD-CTxB was found in lettuce (Fig.1b) . Faint and/or inconsistent recombinant viral protein expression was observed in arugula, Choho Hybrid greens, pepper, spinach, and tomato. Arugula, Choho Hybrid greens and spinach showed no visible chlorosis or necrosis after infiltration, although tomato and pepper leaves developed both chlorosis and necrosis after infiltration. No expression of viral protein was observed in collard greens or radish, and leaves from these plants did not show visible damage from agroinfiltration. Lettuce was selected as the preferred host for edible vaccine production, as it consistently produced the highest expression of RBD-CTxB (based upon immunoblot analyses) and did not exhibit evidence of necrosis after agroinfiltration. We next assessed the optimal parameters to maximize protein expression in this host. We observed comparable expression of RBD-CTxB between leaves infiltrated with an Agrobacterium suspension adjusted to an OD600 of 0.25 and 0.50, with minimal to no visible signs of chlorosis or necrosis (Fig.1c) . Some yellowing was observed in tissue infiltrated at OD600 of 0.75 and 1.0, thus we decided to select an OD600 of 0.5 in subsequent experiments to minimize stress to the plant host (Fig.1d) . We also monitored accumulation of RBD-CTxB at 2 to 10 days post-infiltration (dpi) to determine the timepoint at which expression is highest (Fig.1e ) and damage to tissues was minimal (Fig.1f) . RBD-CTxB expression appears to increase with time to achieve highest levels at 6 dpi, then declines from 8 dpi to 10 dpi. To obtain the highest possible expression of the protein of interest, our data indicate that lettuce plants should be harvested 6 days after infiltration. In summary, this study represents one of the first protocols to express SARS-CoV-2 viral antigen in an edible plant species, a key step towards achieving the goal of developing a plant-based oral vaccine that is protective against COVID-19. Plant-based edible vaccines offer excellent potential towards enhancing equity in vaccine development and distribution in low-income developing countries, many of which report fewer than 2% of citizens as receiving even a single COVID-19 vaccine dose 30 . AMM and TA conceived and designed the project. MP performed all agroinfiltration experiments and immunoblots. MP and AMM contributed to the writing of the manuscript, with edits from TA and JCB. All authors reviewed and approved the manuscript. Plant-made oral vaccines against human infectious diseases-Are we there yet? What does plant-based vaccine technology offer to the fight against COVID-19? Vaccines Overview of expression of hepatitis B surface antigen in transgenic plants Production of hepatitis B surface antigen in transgenic plants for oral immunization Antibody responses in mice stimulated by various doses of the potatoderived major surface antigen of hepatitis B virus Efficient expression of nuclear transgenes in the green alga Chlamydomonas: synthesis of an HIV antigen and development of a new selectable marker Expression of an HBcAg-based antigen carrying angiotensin II in Chlamydomonas reinhardtii as a candidate hypertension vaccine A Plant-Derived Multi-HIV Antigen Induces Broad Immune Responses in Orally Immunized Mice Immunogenic properties of a lettuce-derived C4(V3) Oral delivery of plant-derived HIV-1 p24 antigen in low doses shows a superior priming effect in mice compared to high doses Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model A Chlamydomonas-Derived Human Papillomavirus 16 E7 Vaccine Induces Specific Tumor Protection Induction of a protective immune response to rabies virus in sheep after oral immunization with transgenic maize, expressing the rabies virus glycoprotein Expression of H3N2 nucleoprotein in maize seeds and immunogenicity in mice Expression and immunogenicity of enterotoxigenic escherichia coli heat-labile toxin b subunit in transgenic rice callus Oral immunogenicity of plant-made mycobacterium tuberculosis ESAT6 and CFP10 Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine Expression of the cholera toxin B subunit in maize seeds and a combined mucosal treatment against cholera and traveler's diarrhea Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery Lightinduced production of an antibody fragment and malaria vaccine antigen from Chlamydomonas reinhardtii A chloroplast-derived Toxoplasma gondii GRA4 antigen used as an oral vaccine protects against toxoplasmosis in mice Severe acute respiratory syndrome (SARS) S protein production in plants: Development of recombinant vaccine COVID-19-neutralizing antibodies predict disease severity and survival A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity Improving plant transient expression through the rational design of synthetic 51' and 31' untranslated regions Coronavirus Pandemic (COVID-19) Figure 1. Optimization of expression of the Receptor Binding Domain (RBD) of SARS-CoV-2 a) Schematic depiction of construct used to express RBD in planta. 35S, 35S CaMV promoter. SP, signal peptide PR-1a Nicotiana tabacum (aa 1 -30 aa 522) of the Wuhan-Hu-1 isolate of SARS-CoV-2. CTxB, B subunit of cholera toxin. KDEL, ER retention signal. (b) Anti-FLAG immunoblots to assess relative expression of RBD-CTxB recombinant protein in nine edible plant species with adjusted OD600 as specified in panel. (d) Representative pictures of lettuce infiltrated with A. tumefaciens adjusted to OD600 as specified in panel. Leaf tissue was photographed 6 days post-infiltration of EV and RBD-CTxB. (e) Anti-FLAG immunoblot to assess RBD-CTxB expression over time, in lettuce infiltrated with an adjusted OD600 of 0.50. (f) Representative pictures of lettuce infiltrated with A. tumefaciens adjusted to an OD600 of 0.50. Leaf tissue was photographed 2 to 10 days post-infiltration of EV and RBD-CTxB, as indicated in panel NT, non-transformed lettuce collected (b) 4 days or (c to f) 6 days after infiltration of RBD-CTxB samples. EV, infiltration of A. tumefaciens (pHREAC) We are grateful for helpful discussions and advice from Rima Menassa and colleagues at Agriculture and Agri-Food Canada, Emmanuel Margolin, Edward Rybicki and colleagues from Biopharming Research Unit, University of Cape Town. We gratefully acknowledge the excellent support of Michelle Brazeau, University of Ottawa, in her management of our greenhouse. This study was supported in part by funding from the University of Ottawa Faculty of Science. The authors declare no conflict of interest.